Repositioning Candidate Details
| Candidate ID: | R0691 |
| Source ID: | DB05068 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | ATG002 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process. Unlike protein-derived growth factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and into surrounding tissues. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in diabetic foot ulcers and wounds. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | ATG002 is an agonist of the nicotinic acetylcholine (nACh) receptor pathway (pro-angiogenic drugs). It stimulates the nACh receptor pathway and could be useful in promoting angiogenesis in disease conditions where there is an insufficient supply of blood. |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|